A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients with Growth Hormone Deficiency (AGHD)

Registry ID

EUCTR2010-021523-28

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Ascendis Pharma A/S

Start date

2010-09-02

Last update

2026-08-16

Conditions

• Growth Hormone Deficiency

Summary

The primary objective of the study is to assess the safety and tolerability of ACP-001 under multiple-dose conditions in adults patients with Growth Hormone Deficiency

Locations

• , , Denmark
• , , Austria
• , , Germany
• , , Sweden
• , , Italy

Related clinical trials

• Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
• A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
• A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
• Effects of GH and Lirglutide on AgRP
• A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
• Chromosome 18 Clinical Research Center

View on source registry